Welcome back to Stockhouse
Member Sign In

Email or Username:

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Enter your email address:
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

Get our Best Content in Your Email

You are already a member! Please enter your password to sign in.

Research and Markets: Cariprazine (Major Depressive Disorder) - Forecast and Market Analysis to 2023


Research and Markets ( has announced the addition of the "Cariprazine (Major Depressive Disorder) - Forecast and Market Analysis to 2023" report to their offering.

Cariprazine (RGH-188) is being developed as an adjunctive treatment to antidepressant therapy in patients with MDD who had an inadequate response to antidepressant therapy, and as of April 2014, two Phase III clinical trials were ongoing (Forest Laboratories, NCT01715805; Forest Laboratories, NCT01838876). In addition, cariprazine is being developed for the treatment of schizophrenia and bipolar disorder.


  • Overview of Major depressive disorder, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Cariprazine including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Cariprazine for the top eight countries from 2013 to 2023.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Australia.

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Disease Overview

  • Etiology and Pathophysiology
  • Classification
  • Symptoms and Subtypes of Major Depressive Disorder
  • Prognosis
  • Quality of Life

4 Disease Management

  • Diagnosis
  • Treatment Guidelines and Leading Prescribed Drugs
  • Clinical Practice

5 Competitive Assessment

6 Unmet Needs and Opportunities

  • More Effective Pharmacotherapies
  • More Favorable Side Effect Profiles
  • Rapid Onset of Antidepressant Effects
  • Personalized Treatment Approach

7 Pipeline Assessment

8 Cariprazine (RGH-188)

9 Appendix

For more information visit


Rate this press release
3 stars


Add to favourites icon Add to favourites